PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis

E. G. Garcia; A. Veloso; M. L. Oliveira; J. R. Allen; S. Loontiens; D. Brunson; D. Do; C. Yan; R. Morris; S. Iyer; S. P. Garcia; N. Iftimia; W. Van Loocke; F. Matthijssens; K. McCarthy; J. T. Barata; F. Speleman; T. Taghon; A. Gutierrez; P. Van Vlierberghe; W. Haas; J. S. Blackburn; D. M. Langenau

doi:10.1038/s41375-020-0937-3

PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis

E. G. Garcia, A. Veloso, M. L. Oliveira, J. R. Allen, S. Loontiens, D. Brunson, D. Do, C. Yan, R. Morris, S. Iyer, S. P. Garcia, N. Iftimia, W. Van Loocke, F. Matthijssens, K. McCarthy, J. T. Barata, F. Speleman, T. Taghon, A. Gutierrez, P. Van VlierbergheW. Haas, J. S. Blackburn, D. M. Langenau

Molecular and Cellular Biochemistry

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of thymocytes and is largely driven by the NOTCH/MYC pathway. Yet, additional oncogenic drivers are required for transformation. Here, we identify protein tyrosine phosphatase type 4 A3 (PRL3) as a collaborating oncogenic driver in T-ALL. PRL3 is expressed in a large fraction of primary human T-ALLs and is commonly co-amplified with MYC. PRL3 also synergized with MYC to initiate early-onset ALL in transgenic zebrafish and was required for human T-ALL growth and maintenance. Mass-spectrometry phosphoproteomic analysis and mechanistic studies uncovered that PRL3 suppresses downstream T-cell phosphorylation signaling pathways, including those modulated by VAV1, and subsequently suppresses apoptosis in leukemia cells. Taken together, our studies have identified new roles for PRL3 as a collaborating oncogenic driver in human T-ALL and suggest that therapeutic targeting of the PRL3 phosphatase will likely be a useful treatment strategy for T-ALL.

Original language	English
Pages (from-to)	679-690
Number of pages	12
Journal	Leukemia
Volume	35
Issue number	3
DOIs	https://doi.org/10.1038/s41375-020-0937-3
State	Published - Mar 2021

Bibliographical note

Funding Information:
Acknowledgements We thank Christina Luo, Hiranmayi Ravichan-dran, Rachel Servis, and Ravi Mylvaganam for technical assistance. We thank Drs. Finola Moore and Riadh Lobbardi for helpful discussion and thoughtful review of this manuscript. This work is supported by NIH grant R01CA211734 (DML), R37CA227656 (JSB), CA193651 (AG), the MGH Research Scholar Award (DML), Alex Lemonade Stand Foundation (JSB), the V Foundation for Cancer Research (AG), an Investigatorship from Boston Children’s Hospital (AG), the Research Foundation Flanders (PVV, TT, SL), ‘Kom op tegen Kanker’ (Stand up to Cancer; SL), and the Ghent University Special Research Fund (PVV and TT). Flow cytometry services were supported by MGH Pathology CNY Flow Cytometry Core shared instrumentation grant 1S10RR023440-01A1.

Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41375-020-0937-3

Cite this

Garcia, E. G., Veloso, A., Oliveira, M. L., Allen, J. R., Loontiens, S., Brunson, D., Do, D., Yan, C., Morris, R., Iyer, S., Garcia, S. P., Iftimia, N., Van Loocke, W., Matthijssens, F., McCarthy, K., Barata, J. T., Speleman, F., Taghon, T., Gutierrez, A., ... Langenau, D. M. (2021). PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis. Leukemia, 35(3), 679-690. https://doi.org/10.1038/s41375-020-0937-3

@article{8afd9d8c370045a3844583ff8a723066,

title = "PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis",

abstract = "T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of thymocytes and is largely driven by the NOTCH/MYC pathway. Yet, additional oncogenic drivers are required for transformation. Here, we identify protein tyrosine phosphatase type 4 A3 (PRL3) as a collaborating oncogenic driver in T-ALL. PRL3 is expressed in a large fraction of primary human T-ALLs and is commonly co-amplified with MYC. PRL3 also synergized with MYC to initiate early-onset ALL in transgenic zebrafish and was required for human T-ALL growth and maintenance. Mass-spectrometry phosphoproteomic analysis and mechanistic studies uncovered that PRL3 suppresses downstream T-cell phosphorylation signaling pathways, including those modulated by VAV1, and subsequently suppresses apoptosis in leukemia cells. Taken together, our studies have identified new roles for PRL3 as a collaborating oncogenic driver in human T-ALL and suggest that therapeutic targeting of the PRL3 phosphatase will likely be a useful treatment strategy for T-ALL.",

author = "Garcia, {E. G.} and A. Veloso and Oliveira, {M. L.} and Allen, {J. R.} and S. Loontiens and D. Brunson and D. Do and C. Yan and R. Morris and S. Iyer and Garcia, {S. P.} and N. Iftimia and {Van Loocke}, W. and F. Matthijssens and K. McCarthy and Barata, {J. T.} and F. Speleman and T. Taghon and A. Gutierrez and {Van Vlierberghe}, P. and W. Haas and Blackburn, {J. S.} and Langenau, {D. M.}",

note = "Funding Information: Acknowledgements We thank Christina Luo, Hiranmayi Ravichan-dran, Rachel Servis, and Ravi Mylvaganam for technical assistance. We thank Drs. Finola Moore and Riadh Lobbardi for helpful discussion and thoughtful review of this manuscript. This work is supported by NIH grant R01CA211734 (DML), R37CA227656 (JSB), CA193651 (AG), the MGH Research Scholar Award (DML), Alex Lemonade Stand Foundation (JSB), the V Foundation for Cancer Research (AG), an Investigatorship from Boston Children{\textquoteright}s Hospital (AG), the Research Foundation Flanders (PVV, TT, SL), {\textquoteleft}Kom op tegen Kanker{\textquoteright} (Stand up to Cancer; SL), and the Ghent University Special Research Fund (PVV and TT). Flow cytometry services were supported by MGH Pathology CNY Flow Cytometry Core shared instrumentation grant 1S10RR023440-01A1. Publisher Copyright: {\textcopyright} 2020, The Author(s), under exclusive licence to Springer Nature Limited.",

year = "2021",

month = mar,

doi = "10.1038/s41375-020-0937-3",

language = "English",

volume = "35",

pages = "679--690",

number = "3",

}

Garcia, EG, Veloso, A, Oliveira, ML, Allen, JR, Loontiens, S, Brunson, D, Do, D, Yan, C, Morris, R, Iyer, S, Garcia, SP, Iftimia, N, Van Loocke, W, Matthijssens, F, McCarthy, K, Barata, JT, Speleman, F, Taghon, T, Gutierrez, A, Van Vlierberghe, P, Haas, W, Blackburn, JS & Langenau, DM 2021, 'PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis', Leukemia, vol. 35, no. 3, pp. 679-690. https://doi.org/10.1038/s41375-020-0937-3

TY - JOUR

T1 - PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis

AU - Garcia, E. G.

AU - Veloso, A.

AU - Oliveira, M. L.

AU - Allen, J. R.

AU - Loontiens, S.

AU - Brunson, D.

AU - Do, D.

AU - Yan, C.

AU - Morris, R.

AU - Iyer, S.

AU - Garcia, S. P.

AU - Iftimia, N.

AU - Van Loocke, W.

AU - Matthijssens, F.

AU - McCarthy, K.

AU - Barata, J. T.

AU - Speleman, F.

AU - Taghon, T.

AU - Gutierrez, A.

AU - Van Vlierberghe, P.

AU - Haas, W.

AU - Blackburn, J. S.

AU - Langenau, D. M.

N1 - Funding Information: Acknowledgements We thank Christina Luo, Hiranmayi Ravichan-dran, Rachel Servis, and Ravi Mylvaganam for technical assistance. We thank Drs. Finola Moore and Riadh Lobbardi for helpful discussion and thoughtful review of this manuscript. This work is supported by NIH grant R01CA211734 (DML), R37CA227656 (JSB), CA193651 (AG), the MGH Research Scholar Award (DML), Alex Lemonade Stand Foundation (JSB), the V Foundation for Cancer Research (AG), an Investigatorship from Boston Children’s Hospital (AG), the Research Foundation Flanders (PVV, TT, SL), ‘Kom op tegen Kanker’ (Stand up to Cancer; SL), and the Ghent University Special Research Fund (PVV and TT). Flow cytometry services were supported by MGH Pathology CNY Flow Cytometry Core shared instrumentation grant 1S10RR023440-01A1. Publisher Copyright: © 2020, The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2021/3

Y1 - 2021/3

N2 - T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of thymocytes and is largely driven by the NOTCH/MYC pathway. Yet, additional oncogenic drivers are required for transformation. Here, we identify protein tyrosine phosphatase type 4 A3 (PRL3) as a collaborating oncogenic driver in T-ALL. PRL3 is expressed in a large fraction of primary human T-ALLs and is commonly co-amplified with MYC. PRL3 also synergized with MYC to initiate early-onset ALL in transgenic zebrafish and was required for human T-ALL growth and maintenance. Mass-spectrometry phosphoproteomic analysis and mechanistic studies uncovered that PRL3 suppresses downstream T-cell phosphorylation signaling pathways, including those modulated by VAV1, and subsequently suppresses apoptosis in leukemia cells. Taken together, our studies have identified new roles for PRL3 as a collaborating oncogenic driver in human T-ALL and suggest that therapeutic targeting of the PRL3 phosphatase will likely be a useful treatment strategy for T-ALL.

AB - T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of thymocytes and is largely driven by the NOTCH/MYC pathway. Yet, additional oncogenic drivers are required for transformation. Here, we identify protein tyrosine phosphatase type 4 A3 (PRL3) as a collaborating oncogenic driver in T-ALL. PRL3 is expressed in a large fraction of primary human T-ALLs and is commonly co-amplified with MYC. PRL3 also synergized with MYC to initiate early-onset ALL in transgenic zebrafish and was required for human T-ALL growth and maintenance. Mass-spectrometry phosphoproteomic analysis and mechanistic studies uncovered that PRL3 suppresses downstream T-cell phosphorylation signaling pathways, including those modulated by VAV1, and subsequently suppresses apoptosis in leukemia cells. Taken together, our studies have identified new roles for PRL3 as a collaborating oncogenic driver in human T-ALL and suggest that therapeutic targeting of the PRL3 phosphatase will likely be a useful treatment strategy for T-ALL.

UR - http://www.scopus.com/inward/record.url?scp=85087136592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087136592&partnerID=8YFLogxK

U2 - 10.1038/s41375-020-0937-3

DO - 10.1038/s41375-020-0937-3

M3 - Article

C2 - 32606318

AN - SCOPUS:85087136592

SN - 0887-6924

VL - 35

SP - 679

EP - 690

JO - Leukemia

JF - Leukemia

IS - 3

ER -

PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this